Stock Scorer

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. reported revenue of 1.6M USD for the quarter ending 30 June 2026, down 8.3% from 1.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.6M -8.3%
Gross Profit Q4 '18 · ending 31 December 2018 160K -34.7%
Operating Income Q2 '26 · ending 30 June 2026 -24.2M —
Net Income Q2 '26 · ending 30 June 2026 -21.5M —
Cost of Revenue Q2 '26 · ending 30 June 2026 218K -57.7%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -19.8M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -19.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 142.7M +16.6%
EPS Q2 '26 · ending 30 June 2026 -0.58 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 7.8M-76.4M-64.9M-47.2M
20242024-12-31 18.7M-141.9M-132.1M-20.2M
20232023-12-31 31.2M-97.4M-88.5M-79.6M
20222022-12-31 29.8M-89.9M-86.9M-68.2M
20212021-12-31 6.8M-89.7M-90.9M-52.4M
20202020-12-31 6.5M-50.9M-51M-39.1M
20192019-12-31 4.2M-111.1M-161.4M-98.1M
20182018-12-31 6.2M-84.8M-132.7M-102.2M
20172017-12-31 1.7M-54.4M-68.5M-55.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.6M
Q1 '262026-03-312M
Q4 '252025-12-311.3M
Q3 '252025-09-303.3M
Q2 '252025-06-301.8M
Q1 '252025-03-311.5M
Q4 '242024-12-319.2M
Q3 '242024-09-304.3M
Q2 '242024-06-302.8M
Q1 '242024-03-312.4M
Q4 '232023-12-3117.6M
Q3 '232023-09-309.3M
Q2 '232023-06-301.9M
Q1 '232023-03-312.5M
Q4 '222022-12-317.8M
Q3 '222022-09-3019M
Q2 '222022-06-301.5M
Q1 '222022-03-311.5M
Q4 '212021-12-311.5M
Q3 '212021-09-301.7M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '182018-12-31160K
Q3 '182018-09-30435K
Q2 '182018-06-302.5M
Q1 '182018-03-31151K
Q4 '172017-12-31245K
Q3 '172017-09-30231K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-24.2M
Q1 '262026-03-31-22.2M
Q4 '252025-12-31-22.7M
Q3 '252025-09-30-17.1M
Q2 '252025-06-30-18.4M
Q1 '252025-03-31-18.1M
Q4 '242024-12-31-99.7M
Q3 '242024-09-30-10.5M
Q2 '242024-06-30-12.9M
Q1 '242024-03-31-18.9M
Q4 '232023-12-31-4M
Q3 '232023-09-30-31.6M
Q2 '232023-06-30-31.8M
Q1 '232023-03-31-29.9M
Q4 '222022-12-31-29.1M
Q3 '222022-09-30-20.9M
Q2 '222022-06-30-21M
Q1 '222022-03-31-18.9M
Q4 '212021-12-31-22.9M
Q3 '212021-09-30-20.3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-21.5M
Q1 '262026-03-31-19.8M
Q4 '252025-12-31-19.8M
Q3 '252025-09-30-14.6M
Q2 '252025-06-30-15.4M
Q1 '252025-03-31-15.1M
Q4 '242024-12-31-96.6M
Q3 '242024-09-30-7.6M
Q2 '242024-06-30-11M
Q1 '242024-03-31-16.9M
Q4 '232023-12-31-1.5M
Q3 '232023-09-30-29.3M
Q2 '232023-06-30-29.6M
Q1 '232023-03-31-28.2M
Q4 '222022-12-31-27.6M
Q3 '222022-09-30-20M
Q2 '222022-06-30-20.5M
Q1 '222022-03-31-18.8M
Q4 '212021-12-31-22.8M
Q3 '212021-09-30-21.1M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30218K
Q1 '262026-03-31395K
Q4 '252025-12-31532K
Q3 '252025-09-30538K
Q2 '252025-06-30515K
Q1 '252025-03-31506K
Q4 '242024-12-31705K
Q3 '242024-09-30654K
Q2 '242024-06-30624K
Q1 '242024-03-31809K
Q4 '232023-12-31725K
Q3 '232023-09-30848K
Q2 '232023-06-301M
Q1 '232023-03-31808K
Q4 '222022-12-31877K
Q3 '222022-09-30923K
Q2 '222022-06-301.1M
Q1 '222022-03-311.2M
Q4 '212021-12-311.1M
Q3 '212021-09-301.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-19.8M
Q1 '262026-03-31-18.1M
Q4 '252025-12-31-13.1M
Q3 '252025-09-30-10.9M
Q2 '252025-06-30-10M
Q1 '252025-03-31-13.1M
Q4 '242024-12-31-8.9M
Q3 '242024-09-3022M
Q2 '242024-06-30-12.3M
Q1 '242024-03-31-20.8M
Q4 '232023-12-31-6.8M
Q3 '232023-09-30-24.6M
Q2 '232023-06-30-20.7M
Q1 '232023-03-31-26.4M
Q4 '222022-12-31-19.1M
Q3 '222022-09-30-7.8M
Q2 '222022-06-30-19.7M
Q1 '222022-03-31-21M
Q4 '212021-12-31-17.1M
Q3 '212021-09-30-10.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-19.9M
Q1 '262026-03-31-18.2M
Q4 '252025-12-31-13.2M
Q3 '252025-09-30-11M
Q2 '252025-06-30-10M
Q1 '252025-03-31-13.1M
Q4 '242024-12-31-8.9M
Q3 '242024-09-3022M
Q2 '242024-06-30-12.3M
Q1 '242024-03-31-20.9M
Q4 '232023-12-31-7.2M
Q3 '232023-09-30-24.6M
Q2 '232023-06-30-20.9M
Q1 '232023-03-31-26.9M
Q4 '222022-12-31-19.2M
Q3 '222022-09-30-8M
Q2 '222022-06-30-19.9M
Q1 '222022-03-31-21.1M
Q4 '212021-12-31-17.3M
Q3 '212021-09-30-10.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30142.7M
Q1 '262026-03-31128.8M
Q3 '252025-09-30122.6M
Q2 '252025-06-30122.6M
Q1 '252025-03-31122.4M
Q3 '242024-09-3071.4M
Q2 '242024-06-3071.3M
Q1 '242024-03-3171.1M
Q3 '232023-09-3070.8M
Q2 '232023-06-3070.6M
Q1 '232023-03-3166.9M
Q3 '222022-09-3066.7M
Q2 '222022-06-3066M
Q1 '222022-03-3161.4M
Q3 '212021-09-3061.2M
Q2 '212021-06-3054M
Q1 '212021-03-3150.3M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.58
Q1 '262026-03-31-0.56
Q4 '252025-12-31-0.53
Q3 '252025-09-30-1.58
Q2 '252025-06-30-1.57
Q1 '252025-03-31-1.59
Q4 '242024-12-31-1.71
Q3 '242024-09-30-0.52
Q2 '242024-06-30-0.82
Q1 '242024-03-31-1.09
Q4 '232023-12-31-1.27
Q3 '232023-09-30-1.66
Q2 '232023-06-30-1.55
Q1 '232023-03-31-1.44
Q4 '222022-12-31-1.33
Q3 '222022-09-30-1.29
Q2 '222022-06-30-1.34
Q1 '222022-03-31-1.37
Q4 '212021-12-31-1.63
Q3 '212021-09-30-1.56